iNtODEWORLD | Our research is committed to finding effective treatment for life-threatening infectious diseases.
15234
home,page,page-id-15234,page-template,page-template-full_width,page-template-full_width-php,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

iNtODEWORLD

A Game Changer in Antibacterial Drugs for Superbugs and Persister Cells

We are committed to finding effective treatment for life-threatening infectious diseases.

maintopban1

A Game Changer in Antibacterials Treatment for Gram-negative bacteria, Ultimate Target of N-Rephasin® Technology

maintopban2

Eco-friendly, no Side-effects, Unique mode of action. Bacteriophages and Antibiotic Resistance in Bacteria

maintopban3

Opening a New Era in Anti-Fugal Agents. A New Type of Antifungal Agent, iN-EYD34

maintopban4

New Generation of Heme-Iron (Porphyrin-Fe) Novel concept iron deficiency anemia therapeutic agent

iNtRON Biotechnology, Inc.

iNtRON Bio has been focusing on the R&D investment since its foundation and accelerates development speed after the IPO in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.

INSIDE iNtRON

  • To Focus on Investor Relations and Global Business Development As iNtRON Biotechnology (hereafter “iNtRON”) has grown up steadily, iNtRON has opened a new Seoul Office in the center of Seoul with great accessibility to focus on global business and investor relations. iNtRON is developing novel......

  • “Nightmare bacteria” with the power to resist most antibiotics are popping up across the U.S., but new, aggressive policies can help stop them from spreading, federal health officials said Tuesday. A new program for testing suspect bacteria turned up unusual antibiotic-resistance genes 221 times in......

  • In January 2018, The Catholic University of Korea’s Division of Infectious Disease released a paper on the subject of seriousness of multidrug-resistant organisms (MDROs) and suggested control methods to prevent bacterial epidemic disease occurrence. Seriousness of MDROs MDROs including Carbapenem resistance bacteria or well known......

See All
seh

PIPELINES

iNtRON Bio has been focusing on the R&D investment since its foundation and accelerate development speed after the IPD in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.

iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.